Guillain-Barré syndrome related to COVID-19 infection
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 2, 2020
- Accepted in final form April 13, 2020
- First Published April 29, 2020.
Author Disclosures
- Paola Alberti, MD, PhD*,
- Simone Beretta, MD, PhD*,
- Marco Piatti, MD,
- Aristotelis Karantzoulis, MD,
- Maria Luisa Piatti, MD,
- Patrizia Santoro, MD,
- Martina Viganò, MD,
- Ginevra Giovannelli, MD,
- Fiammetta Pirro, MD,
- Danilo Antonio Montisano, MD,
- Ildebrando Appollonio, MD and
- Carlo Ferrarese, MD, PhD
- Paola Alberti, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simone Beretta, MD, PhD*,
NONE
NONE
NONE
Associated Editor, Frontiers in Neurology, from May 2019, I do not received compansation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Piatti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aristotelis Karantzoulis, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Luisa Piatti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrizia Santoro, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martina Viganò, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ginevra Giovannelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fiammetta Pirro, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Danilo Antonio Montisano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ildebrando Appollonio, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carlo Ferrarese, MD, PhD
Scientific Advisory Board of Gantenerumab Study (Roche) Scientific Advisory Board of Merck Scientific Advisory Board od DOC Scientific Advisory Board of Biogen
NONE
Travel reimbursement from Roche to attend Advisory Board of Gatenerumab in San Diego (Nov. 2013) Travel reimbursement from Merck to attend Advisory Board (Rome, March 2018)
Member of editorial board of Neurological Sciences since 2011. No compensation Associate Editor of Parkinson Disease (no compensation)
NONE
Textbook: Malattie del sistema nervoso, McGraw Hill, 2016
NONE
NONE
NONE
NONE
NONE
1. Roche 2. Merck 3. Biogen 4. DOC
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
- Correspondence
Dr. Alberti paola.alberti{at}unimib.it
Article usage
Cited By...
Letters: Rapid online correspondence
- RE: Guillain-Barre Syndrome Related to COVID-19 Infection. Comments after 16 published cases
- Cristina Guijarro-Castro, Neurologist. School of Medicine Professor, CINAC Puerta del Sur
Submitted May 20, 2020
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.